Kiniksa Pharmaceuticals is Still Undervalued Despite Dropping ARDS
<p><a href='https://financialmodelingprep.com/financial-summary/KNSA'>Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) </a>made an announcement, according to which its Ph 3 portion of the Ph 2/3 trial of mavrilimumab in COVID-19-Related acute respiratory syndrome (ARDS) has failed to meet the primary endpoint of the study related to the proportion of patients alive and free of mechanical ventilation.</p>
<p>While dropping ARDS from their model, analysts at Wedbush still believe the company is undervalued, mentioning the early reports pointing to a rapid acceleration of ARCALYST sales, which remains the value driver for Kiniksa Pharmaceuticals.</p>

NASDAQ:KNSA